Intercept Platelet System (IPS): Phase III trial update

Cerus Corp. (CERS), Concord, Calif. Product: Intercept Platelet System (IPS) Business: Blood products/substitutes Therapeutic category: Viral infection, Cell replacement Target: Nucleic acids Descrip...